FCARH143

Overview

FCARH143 is a BCMA targeted CAR T Cell therapy being developed at the Fred Hutchinson Cancer Research Center in collaboration with Juno Therapeutics and the National Cancer Institute.

SparkCures ID 336
Generic Name FCARH143
Additional Names Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.